Actionable news
0
All posts from Actionable news
Actionable news in PETX: Aratana Therapeutics, Inc.,

Catalysts Mounting For These 2 Biotechs

Summary

One of the keys in successfully investing in the currently beaten down small biotech space is an awareness of upcoming catalysts that could trigger a rally for these stocks.

These events include upcoming presentations, trial milestones, and PDUFA dates with the FDA to name a few.

Here are two attractive small cap stocks that biotech investors should get acquainted with before potential catalysts hit in June. Both have signed recent lucrative collaboration deals.

One of the most important things that an investor must do to be successful in investing in the currently beaten down small cap biotech space, besides being solidly diversified and practicing patience; is a keen awareness of upcoming potential catalysts that could be triggers for upside appreciation or declines in that underlying stock. These include upcoming trial milestone dates, presentations at industry events or investor conferences, PDUFA dates with the FDA, impact of collaboration deals and possible secondary offerings that could dilute current shareholders.

Here are two attractive small biotech companies with potential catalysts coming up soon that have already entered into significant collaboration deals recently.

Ariad (NASDAQ:ARIA) was already on my list to talk about after making a small purchase on Friday after the sector was in the middle of its third straight week of declines and after I noted the analyst activity on it on that day's Biotech Forum Daily Digest. News broke this morning that the company has entered into a major transaction that should benefit shareholders.

The company announced this morning that it is selling its European operations to Incyte (NASDAQ:INCY). This larger industry player will acquire all the shares in ARIAD Pharmaceuticals' European entity as well as an exclusive license to develop and commercialize ARIAD's drug Iclusig in Europe and 22 other countries. ARIAD will retain...


More